Trials / Terminated
TerminatedNCT00581243
Study Evaluating Safety and Tolerability of Ascending Multiple Dose of SLV-313 in Schizophrenia Patients
An Ascending Multiple-Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of SLV-313 Sustained-Release (SR) Tablets Administered Orally to Subjects With Schizophrenia and Schizoaffective Disorder
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
Randomized, inpatient, ascending multiple dose study given to subjects with schizophrenia and schizoaffective disorder to assess safety and tolerability.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SLV-313 SR | sustained relase tablets taken once daily for 14 days |
Timeline
- Start date
- 2008-01-01
- Primary completion
- 2008-05-01
- Completion
- 2008-05-01
- First posted
- 2007-12-27
- Last updated
- 2022-05-03
Source: ClinicalTrials.gov record NCT00581243. Inclusion in this directory is not an endorsement.